To include your compound in the COVID-19 Resource Center, submit it here.

Amgen/UCB osteoporosis therapy gets CRL

By Alicia Parker | Jul 17, 2017 | 9:52 PM GMT

Amgen Inc. (NASDAQ:AMGN) and UCB S.A. (Euronext:UCB) said FDA issued a complete response letter for Evenity romosozumab to

Read the full 181 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE